Key Drivers
- Strong Liquidity
- Heavy Cash Burn
- No Revenue
AIAI Summary
PCVX is now best viewed as a late-stage, cash-rich biotech catalyst trade—its strong balance sheet reduces dilution risk, but the stock's current valuation and rally are only justified if VAX-31 delivers convincing Phase 3 efficacy and safety, making the upcoming readout the decisive inflection point.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Heavy Cash Burn
- •No Revenue
PCVX has a very strong, low-debt balance sheet and improving book value, but with no revenue and ongoing heavy cash losses, its near-term financial strength is offset by persistent burn.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Breakout support
- •Stretched rally
PCVX has shifted into a short-term uptrend over the last month, holding its breakout area but now needing a clean push above $58 as the rally looks stretched.
Fast recovery from the early-June low to a new peak on 2026-07-02 suggests short-term extension risk
Sentiment & News
Similar Companies in Healthcare
Other companies in the same sector with AI ratings